Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued on Thursday,Benzinga reports. They presently have a $151.00 price target on the stock. BTIG Research’s target price points to a potential upside of 143.82% from the stock’s current price.

Several other analysts have also commented on ORKA. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research report on Monday, April 27th. UBS Group boosted their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Finally, Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Price Performance

ORKA opened at $61.93 on Thursday. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -31.92 and a beta of -0.20. The company’s 50 day simple moving average is $55.17 and its two-hundred day simple moving average is $39.33. Oruka Therapeutics has a 1-year low of $9.40 and a 1-year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, equities analysts anticipate that Oruka Therapeutics will post -2.2 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joana Goncalves sold 7,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $61.85, for a total transaction of $432,950.00. Following the completion of the transaction, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $2,064,367.45. This trade represents a 17.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 30,765 shares of company stock valued at $1,522,695 over the last ninety days. Corporate insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Several large investors have recently modified their holdings of the business. Fairmount Funds Management LLC grew its position in shares of Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares during the last quarter. Viking Global Investors LP acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $51,280,000. Deep Track Capital LP boosted its position in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. boosted its position in Oruka Therapeutics by 38.1% during the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after acquiring an additional 676,865 shares during the last quarter. Finally, RTW Investments LP boosted its position in Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.